Balchem (BCPC) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Balchem in October 2026.
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Balchem (BCPC) Stock Forecast
Analyst price target, next 12 months
$190.71
+11.4% vs today's $171.25
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Balchem have a consensus 12-month target of $190.71, above the current price of $171.25.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Balchem’s stock with a target price of $190.71, indicating potential growth.
Financial Health
Balchem Corp is performing well with strong revenue, cash flow, and profit margins.
Dividend
Balchem Corp's dividend yield of 0.56% is low, indicating limited income from dividends. If you invested $1000, you would be paid $5.60 a year in dividends (based on the last 12 months).
Baskets Featuring BCPC
Next-Gen Infant Nutrition (Human Milk Alternatives)
A $53 million jury verdict against Abbott over its cow-milk-based preterm infant formula is exposing major manufacturers to sweeping legal liabilities. This disruption paves the way for specialized pediatric nutrition companies and human milk alternative providers to capture critical market share in neonatal healthcare.
Published: 10 April 2026
Explore BasketFood Safety Investing: The Next Chapter Unfolds
Recent recalls of baby formula by Danone and other major brands, traced back to a single contaminated ingredient supplier, have exposed significant risks in the global supply chain. This situation creates a potential investment opportunity in companies focused on food safety, testing, and alternative brands with more secure sourcing.
Published: 24 January 2026
Explore BasketCompare Balchem with other stocks
Molson Coors vs Balchem
Molson Coors vs Balchem
Sprouts vs Balchem
Sprouts vs Balchem: A neutral business comparison.
Ingredion vs Balchem
Ingredion vs Balchem
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
